BMS announces mixed results of lung cancer drug Opdivo - Pharmaceutical Business Review

BMS announces mixed results of lung cancer drug Opdivo  Pharmaceutical Business Review

Bristol-Myers Squibb (BMS) has announced the mixed results from the phase 3 CheckMate -222 trial of the lung cancer drug Opdivo (nivolumab).